479 related articles for article (PubMed ID: 18174269)
1. Improved estimation of glomerular filtration rate by serum cystatin C in preventing contrast induced nephropathy by N-acetylcysteine or zinc--preliminary results.
Kimmel M; Butscheid M; Brenner S; Kuhlmann U; Klotz U; Alscher DM
Nephrol Dial Transplant; 2008 Apr; 23(4):1241-5. PubMed ID: 18174269
[TBL] [Abstract][Full Text] [Related]
2. Is treatment with N-acetylcysteine to prevent contrast-induced nephropathy when using bicarbonate hydration out of date?
Heng AE; Cellarier E; Aublet-Cuvelier B; Decalf V; Motreff P; Marcaggi X; Deteix P; Souweine B
Clin Nephrol; 2008 Dec; 70(6):475-84. PubMed ID: 19049703
[TBL] [Abstract][Full Text] [Related]
3. N-acetylcysteine versus AScorbic acid for preventing contrast-Induced nephropathy in patients with renal insufficiency undergoing coronary angiography NASPI study-a prospective randomized controlled trial.
Jo SH; Koo BK; Park JS; Kang HJ; Kim YJ; Kim HL; Chae IH; Choi DJ; Sohn DW; Oh BH; Park YB; Choi YS; Kim HS
Am Heart J; 2009 Mar; 157(3):576-83. PubMed ID: 19249432
[TBL] [Abstract][Full Text] [Related]
4. Effect of N-acetylcysteine on cystatin C-based renal function after elective coronary angiography (ENABLE Study): a prospective, randomized trial.
Kim BJ; Sung KC; Kim BS; Kang JH; Lee KB; Kim H; Lee MH
Int J Cardiol; 2010 Feb; 138(3):239-45. PubMed ID: 18793808
[TBL] [Abstract][Full Text] [Related]
5. Comparison of combination therapy of high-dose oral N-acetylcysteine and intravenous sodium bicarbonate hydration with individual therapies in the reduction of Contrast-induced Nephropathy during Cardiac Catheterisation and Percutaneous Coronary Intervention (CONTRAST): A multi-centre, randomised, controlled trial.
Chong E; Poh KK; Lu Q; Zhang JJ; Tan N; Hou XM; Ong HY; Azan A; Chen SL; Chen JY; Ali RM; Fang WY; Lau TW; Tan HC
Int J Cardiol; 2015 Dec; 201():237-42. PubMed ID: 26301645
[TBL] [Abstract][Full Text] [Related]
6. Does intravenous or oral high-dose N-acetylcysteine in addition to saline prevent contrast-induced nephropathy assessed by cystatin C?
Erturk M; Uslu N; Gorgulu S; Akbay E; Kurtulus G; Akturk IF; Akgul O; Surgit O; Uzun F; Gul M; Isiksacan N; Yildirim A
Coron Artery Dis; 2014 Mar; 25(2):111-7. PubMed ID: 24365793
[TBL] [Abstract][Full Text] [Related]
7. Renal Insufficiency Following Contrast Media Administration Trial (REMEDIAL): a randomized comparison of 3 preventive strategies.
Briguori C; Airoldi F; D'Andrea D; Bonizzoni E; Morici N; Focaccio A; Michev I; Montorfano M; Carlino M; Cosgrave J; Ricciardelli B; Colombo A
Circulation; 2007 Mar; 115(10):1211-7. PubMed ID: 17309916
[TBL] [Abstract][Full Text] [Related]
8. Prevention of contrast-induced nephropathy by N-acetylcysteine in critically ill patients: different definitions, different results.
Chousterman BG; Bouadma L; Moutereau S; Loric S; Alvarez-Gonzalez A; Mekontso-Dessap A; Laissy JP; Rahmouni A; Katsahian S; Brochard L; Schortgen F
J Crit Care; 2013 Oct; 28(5):701-9. PubMed ID: 23683568
[TBL] [Abstract][Full Text] [Related]
9. N-acetylcysteine in preventing contrast-induced nephropathy assessed by cystatin C.
Alioglu E; Saygi S; Turk U; Kirilmaz B; Tuzun N; Duman C; Tengiz I; Yildiz S; Ercan E
Cardiovasc Ther; 2013 Jun; 31(3):168-73. PubMed ID: 22212518
[TBL] [Abstract][Full Text] [Related]
10. Acetylcysteine in the prevention of contrast-induced nephropathy after coronary angiography.
Oldemeyer JB; Biddle WP; Wurdeman RL; Mooss AN; Cichowski E; Hilleman DE
Am Heart J; 2003 Dec; 146(6):E23. PubMed ID: 14661012
[TBL] [Abstract][Full Text] [Related]
11. A randomized trial of intravenous n-acetylcysteine to prevent contrast induced nephropathy in acute coronary syndromes.
Jaffery Z; Verma A; White CJ; Grant AG; Collins TJ; Grise MA; Jenkins JS; McMullan PW; Patel RA; Reilly JP; Thornton SN; Ramee SR
Catheter Cardiovasc Interv; 2012 May; 79(6):921-6. PubMed ID: 21542122
[TBL] [Abstract][Full Text] [Related]
12. N-acetylcysteine and/or ascorbic acid versus placebo to prevent contrast-induced nephropathy in patients undergoing elective cardiac catheterization: The NAPCIN trial; A single-center, prospective, randomized trial.
Habib M; Hillis A; Hammad A
Saudi J Kidney Dis Transpl; 2016 Jan; 27(1):55-61. PubMed ID: 26787567
[TBL] [Abstract][Full Text] [Related]
13. Renal Insufficiency Following Radiocontrast Exposure Trial (REINFORCE): a randomized comparison of sodium bicarbonate versus sodium chloride hydration for the prevention of contrast-induced nephropathy.
Adolph E; Holdt-Lehmann B; Chatterjee T; Paschka S; Prott A; Schneider H; Koerber T; Ince H; Steiner M; Schuff-Werner P; Nienaber CA
Coron Artery Dis; 2008 Sep; 19(6):413-9. PubMed ID: 18955835
[TBL] [Abstract][Full Text] [Related]
14. Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention: a randomized controlled trial.
Kay J; Chow WH; Chan TM; Lo SK; Kwok OH; Yip A; Fan K; Lee CH; Lam WF
JAMA; 2003 Feb; 289(5):553-8. PubMed ID: 12578487
[TBL] [Abstract][Full Text] [Related]
15. N-Acetylcysteine does not artifactually lower plasma creatinine concentration.
Haase M; Haase-Fielitz A; Ratnaike S; Reade MC; Bagshaw SM; Morgera S; Dragun D; Bellomo R
Nephrol Dial Transplant; 2008 May; 23(5):1581-7. PubMed ID: 18202091
[TBL] [Abstract][Full Text] [Related]
16. Intravenous N-acetylcysteine plus high-dose hydration versus high-dose hydration and standard hydration for the prevention of contrast-induced nephropathy: CASIS--a multicenter prospective controlled trial.
Koc F; Ozdemir K; Kaya MG; Dogdu O; Vatankulu MA; Ayhan S; Erkorkmaz U; Sonmez O; Aygul MU; Kalay N; Kayrak M; Karabag T; Alihanoglu Y; Gunebakmaz O
Int J Cardiol; 2012 Mar; 155(3):418-23. PubMed ID: 21106264
[TBL] [Abstract][Full Text] [Related]
17. Effect of N-acetylcysteine on renal function in patients with chronic kidney disease.
Mainra R; Gallo K; Moist L
Nephrology (Carlton); 2007 Oct; 12(5):510-3. PubMed ID: 17803476
[TBL] [Abstract][Full Text] [Related]
18. Preventive strategies of renal insufficiency in patients with diabetes undergoing intervention or arteriography (the PREVENT Trial).
Lee SW; Kim WJ; Kim YH; Park SW; Park DW; Yun SC; Lee JY; Kang SJ; Lee CW; Lee JH; Choi SW; Seong IW; Suh J; Cho YH; Lee NH; Cheong SS; Yoo SY; Lee BK; Lee SG; Hyon MS; Shin WY; Lee SW; Jang JS; Park SJ
Am J Cardiol; 2011 May; 107(10):1447-52. PubMed ID: 21420063
[TBL] [Abstract][Full Text] [Related]
19. I.v. N-acetylcysteine and emergency CT: use of serum creatinine and cystatin C as markers of radiocontrast nephrotoxicity.
Poletti PA; Saudan P; Platon A; Mermillod B; Sautter AM; Vermeulen B; Sarasin FP; Becker CD; Martin PY
AJR Am J Roentgenol; 2007 Sep; 189(3):687-92. PubMed ID: 17715118
[TBL] [Abstract][Full Text] [Related]
20. Effect of N-acetylcysteine on serum creatinine and kidney function: results of a randomized controlled trial.
Moist L; Sontrop JM; Gallo K; Mainra R; Cutler M; Freeman D; House AA
Am J Kidney Dis; 2010 Oct; 56(4):643-50. PubMed ID: 20541301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
